INSPIRE: INnovative SABR for Prostate Cancer All IREland

This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermediate, and eligible high-risk prostate cancer. Eligible patients will receive next generation prostate SABR incorporating toxicity reduction strategies

Trial Details

NCT ID
NCT07552168
Phase
PHASE2
Sponsor
Cancer Trials Ireland
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Next generation Stereotactic Ablative Radiotherapy (SABR)
Locations (sample)
  • Dublin, Leinster, Ireland|53.33306,-6.24889
  • Cork, Ireland|51.89797,-8.47061
  • Waterford, Ireland|52.25833,-7.11194
  • Belfast, Ulster, United Kingdom|54.59682,-5.92541

Key Eligibility Criteria

  • Written informed consent obtained prior to any study-related procedures
  • Males ≥ 18 years of age
  • ECOG performance status (PS) 0-2
  • Biopsy-proven prostate adenocarcinoma without neuro-endocrine differentiation (within 18 months prior to registration, unless on active surveillanc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →